Novo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of "Hold" from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) have been assigned a consensus rating of "Hold" from the twelve analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $128.00.

Several research firms recently issued reports on NVO. BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd.

Novo Nordisk A/S Stock Up 2.8%

Shares of Novo Nordisk A/S stock opened at $74.70 on Friday. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $335.22 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The business has a fifty day simple moving average of $65.87 and a 200 day simple moving average of $80.71.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of large investors have recently modified their holdings of NVO. Victory Capital Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after acquiring an additional 23,223 shares in the last quarter. Bryn Mawr Capital Management LLC raised its position in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after acquiring an additional 30,420 shares in the last quarter. DSM Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 16.7% in the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock worth $172,678,000 after acquiring an additional 286,912 shares in the last quarter. Channing Global Advisors LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth approximately $354,000. Finally, Compagnie Lombard Odier SCmA raised its stake in Novo Nordisk A/S by 5.0% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 67,745 shares of the company's stock worth $5,827,000 after buying an additional 3,200 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.